Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Enrico Franceschi(Medica (Italy)), Alba A. Brandes(Istituti di Ricovero e Cura a Carattere Scientifico)

British Journal of Cancer

March 13, 2007

10.1038/sj.bjc.6603669

Cited by 212

Related Papers

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

|British Journal of Cancer|2006|228